You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

CLINICAL TRIALS PROFILE FOR OMACETAXINE MEPESUCCINATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Omacetaxine Mepesuccinate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002574 ↗ Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 2 1994-09-01 Phase II trial to study the effectiveness of homoharringtonine and interferon alfa in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells.
NCT00003239 ↗ Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 2 1998-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and homoharringtonine and biological therapy with interferon alfa in treating patients with chronic phase chronic myelogenous leukemia.
NCT00003239 ↗ Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Completed M.D. Anderson Cancer Center Phase 2 1998-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and homoharringtonine and biological therapy with interferon alfa in treating patients with chronic phase chronic myelogenous leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Omacetaxine Mepesuccinate

Condition Name

Condition Name for Omacetaxine Mepesuccinate
Intervention Trials
Chronic Myeloid Leukemia 3
FLT3-ITD Mutation 2
AML 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Omacetaxine Mepesuccinate
Intervention Trials
Leukemia, Myeloid 10
Leukemia 10
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Omacetaxine Mepesuccinate

Trials by Country

Trials by Country for Omacetaxine Mepesuccinate
Location Trials
United States 33
France 3
India 2
Singapore 2
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Omacetaxine Mepesuccinate
Location Trials
Texas 9
New York 4
Indiana 3
Massachusetts 3
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Omacetaxine Mepesuccinate

Clinical Trial Phase

Clinical Trial Phase for Omacetaxine Mepesuccinate
Clinical Trial Phase Trials
Phase 2 10
Phase 1/Phase 2 4
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Omacetaxine Mepesuccinate
Clinical Trial Phase Trials
Completed 9
Terminated 4
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Omacetaxine Mepesuccinate

Sponsor Name

Sponsor Name for Omacetaxine Mepesuccinate
Sponsor Trials
National Cancer Institute (NCI) 5
ChemGenex Pharmaceuticals 4
Teva Branded Pharmaceutical Products R&D, Inc. 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Omacetaxine Mepesuccinate
Sponsor Trials
Industry 16
Other 7
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Omacetaxine Mepesuccinate: Clinical Trials, Market Analysis, and Projections

Introduction

Omacetaxine mepesuccinate, marketed under the brand name Synribo, is a cephalotaxine ester and protein synthesis inhibitor that has garnered significant attention for its efficacy in treating chronic myeloid leukemia (CML), particularly in patients resistant or intolerant to tyrosine kinase inhibitors (TKIs). Here, we delve into the clinical trials, market analysis, and future projections for this drug.

Clinical Trials Overview

Phase II and III Trials

Omacetaxine mepesuccinate has undergone extensive clinical trials to assess its efficacy and safety. Phase II and III trials have focused on its use in patients with CML who are resistant to or intolerant of two or more TKIs, such as imatinib, dasatinib, and nilotinib. These trials have shown promising results, with patients achieving significant hematologic and cytogenetic responses[3][4].

Efficacy in CML with T315I Mutation

A notable aspect of omacetaxine mepesuccinate is its activity against cells harboring the BCR-ABL T315I mutation, which is highly resistant to current TKIs. Phase 2 trials have demonstrated that omacetaxine can induce complete hematologic responses and major cytogenetic responses in these patients, highlighting its unique therapeutic value[5].

Safety and Tolerability

Clinical trials have generally shown that omacetaxine mepesuccinate is well-tolerated, although it can cause adverse events such as QT interval prolongation and other common side effects associated with anticancer therapies. The subcutaneous formulation has been particularly noted for its safety and efficacy profile[1][5].

FDA Approval and Regulatory Status

Accelerated and Full Approval

Omacetaxine mepesuccinate received accelerated approval from the FDA in October 2012 for the treatment of adults with chronic-phase or accelerated-phase CML who were resistant or intolerant to two or more TKIs. Following additional clinical trial data, the FDA granted full approval in 2014 based on the final analysis of two phase II trials[3][4].

Orphan Drug Designation

The drug received Orphan Drug designation from both the EMEA and FDA in 2005 and 2006, respectively, and was also granted Fast Track designation by the FDA in November 2006, reflecting its potential to address an unmet medical need[2].

Market Analysis

Target Market

The primary target market for omacetaxine mepesuccinate is patients with CML who have failed or are intolerant to multiple TKIs. Given the limited treatment options for these patients, omacetaxine mepesuccinate fills a critical gap in the therapeutic landscape.

Market Size and Growth

The market for CML treatments is growing, driven by the increasing incidence of the disease and the need for effective therapies beyond first-line TKIs. Omacetaxine mepesuccinate, with its unique mechanism of action and efficacy in TKI-resistant patients, is poised to capture a significant share of this market.

Competitive Landscape

While TKIs remain the first-line treatment for CML, omacetaxine mepesuccinate offers a distinct advantage for patients who have failed these therapies. Its competitive edge lies in its ability to target cells with the T315I mutation and its role as a protein synthesis inhibitor, which differentiates it from other CML treatments[2][5].

Projections and Future Outlook

Expanding Indications

Ongoing and future clinical trials are expected to explore the use of omacetaxine mepesuccinate in other hematological malignancies, such as acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). This could further expand its market potential and therapeutic utility[1].

Alternative Formulations

The development of intravenous, subcutaneous, and oral formulations of omacetaxine mepesuccinate is underway. These alternative formulations are likely to enhance patient compliance and expand the drug's reach, contributing to its growth in the market[1].

Global Reach

With its FDA approval and potential for approval in other regions, omacetaxine mepesuccinate is set to become a global player in the CML treatment market. Its unique benefits and the growing need for effective treatments in this space position it for significant market penetration.

Key Takeaways

  • Clinical Efficacy: Omacetaxine mepesuccinate has demonstrated significant efficacy in patients with CML who are resistant or intolerant to TKIs, including those with the T315I mutation.
  • Regulatory Approval: The drug has received full FDA approval and Orphan Drug designation, highlighting its therapeutic value.
  • Market Potential: With a growing market for CML treatments and its unique competitive advantages, omacetaxine mepesuccinate is poised for significant market growth.
  • Future Directions: Ongoing and future clinical trials will explore its use in other hematological malignancies and alternative formulations, further expanding its therapeutic and market potential.

FAQs

What is omacetaxine mepesuccinate used for?

Omacetaxine mepesuccinate is used for the treatment of chronic myeloid leukemia (CML) in patients who are resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs)[2].

How does omacetaxine mepesuccinate work?

Omacetaxine mepesuccinate is a protein synthesis inhibitor that prevents the production of Bcr-Abl and Mcl-1, proteins that drive CML. It is effective against cells with the T315I mutation, which is resistant to TKIs[3].

What are the common side effects of omacetaxine mepesuccinate?

Common side effects include QT interval prolongation, thrombocytopenia, anemia, and other hematologic adverse events[1].

Is omacetaxine mepesuccinate approved for other indications?

Currently, omacetaxine mepesuccinate is approved only for CML. However, clinical trials are ongoing to explore its use in other hematological malignancies such as AML and MDS[1].

How is omacetaxine mepesuccinate administered?

Omacetaxine mepesuccinate can be administered subcutaneously, and intravenous and oral formulations are under development[1].

Sources

  1. Aetna: Omacetaxine Mepesuccinate (Synribo) - Medical Clinical Policy Bulletin.
  2. DrugBank: Omacetaxine mepesuccinate: Uses, Interactions, Mechanism of Action.
  3. The Hospitalist: Omacetaxine mepesuccinate gets full FDA approval.
  4. ASCO Post: Omacetaxine Mepesuccinate Receives Full FDA Approval for CML.
  5. Blood: Phase 2 study of subcutaneous omacetaxine mepesuccinate after failure of tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia.
Last updated: 2025-01-07

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.